Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 1 of about 1   

Articles published

NVS 94.61 +0.04 (0.04%)
price chart
Roche Building On Its Strengths
With other drugs like Zelboraf and T-DM1 on the way (Zelboraf is approved, T-DM1 likely will be in 2013), Roche looks poised to stretch its lead on Novartis (NVS), Sanofi, and AstraZeneca in oncology. What's more, while Regeneron's (REGN) Eylea may ...